GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Infinity Pharmaceuticals, Inc. (INFI) [hlAlert]

Infinity Pharmaceuticals, Inc. (IPI) has developed a pipeline of product candidates for multiple cancer indications. The Company?s lead product candidate, retaspimycin hydrochloride (IPI-504) is an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a central component of the cellular
chaperone system, which supports and stabilizes cancer-causing proteins, such as c-Kit, EGFR, and HER2, enabling multiple forms of cancer to thrive. Inhibition of the Hsp90 chaperone knocks out this critical source of support for cancer cells, leading to tumor growth inhibition and cancer cell death. In October 2008, the commenced an international Phase III registration study of IPI-504 in patients with refractory gastrointestinal stromal tumors (GIST), based on the activity and safety data from a Phase I trial reported during the year ended December 31, 2008.
.
( Total: 17 Current Stock Recommendations )
Infinity Pharmaceuticals, Inc.   (17)
Sell Hold 41% Buy 47%
Related companies
China Biologic ...   (4)
Buy 100%
ATHERSYS INC   (7)
Buy 100%
ACURA PHARMACEUTICAL   (2)
Buy 100%
BioSpecifics ...   (5)
Buy 100%
Derma Sciences, Inc.   (2)
Buy 100%
Tenax Therapeutics ...   (2)
Buy 100%
ARCA BIOPHARMA INC.   (1)
Buy 100%
PROLOR Biotech, Inc.   (5)
Buy 100%
Opko Health Inc   (2)
Buy 100%
Nutraceutical ...   (1)
Buy 100%
Show  

Date (ET)MemberRatingYTD
Gains
 
10/20/2014  
Hold
  
5/7/2013  
Hold
  
3/4/2014  
Sell
  
11/7/2012  
Hold
  
5/7/2015  
Buy
  
5/9/2013  
Buy
  
2/20/2013  
Buy
  
1/5/2012  
Hold
  
10/31/2008  
Buy
  
3/6/2013  
Buy
  
1/31/2013  
Buy
  
8/24/2012  
Hold
  
4/16/2009  
Sell
  
8/3/2007  
Buy
  
4/2/2013  
Hold
  
7/12/2007  
Buy
  
12/12/2013  
Hold
  

* As of 8/27/2015 12:00 AM
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy